Clinical Trial Finder

Inclusion Criteria.

• - Children who have not been treated with long-term targeted PAH drug therapy, which include calcium channel blockers (CCB); prostanoids, endothelin receptor antagonists (ERA) or PDE-5 inhibitors (PDE5i) (note that agents used for vasoreactivity testing during cardiac catheterization, or for acute periprocedural stabilization will be discontinued prior to study enrollment these include inhaled nitric oxide and/or prostacyclin analogs) a.

Children who have been receiving subtherapeutic dosing of sildenafil (and no other standing therapy) for less than 2 weeks at the time of their referral for evaluation at a PH Center, may be included after a washout period of two days. Subtherapeutic is defined as dosage less than those shown in Section 6.1.2 sildenafil dosing chart. If, prior to the initial diagnostic cardiac catheterization, the independent clinical practitioner is planning to stop low dose sildenafil that is judged to not have therapeutic impact on hemodynamics by echocardiography, one may include this candidate for enrollment. These children will be followed closely during the washout period for clinical findings of cardiorespiratory changes, and with echocardiography and NT-proBNP measurements. Abnormal findings on these screening tests will prompt consideration of acute initiation of inhaled nitric oxide therapy. Therapy for pulmonary hypertension as determined by randomization for the study, may be started immediately after the two day washout period.

• - Diagnosis of PAH by cardiology diagnostics.

1. Diagnosis by cardiac catheterization with in the previous six months: PAH is defined as the presence of mean pulmonary artery pressure > 25mmHg, pulmonary capillary wedge pressure (or left atrial or left ventricular end diastolic pressure) ≤ 15 mmHg, and pulmonary vascular resistance index (PVRI) > 3 Woods Units. 2. For infants less than one year of age for whom cardiac catheterization is not considered as part of the clinical team's recommended approach, enrollment will be possible without catheterization if the following four criteria are met: i. Two separate echocardiograms clearly demonstrate pulmonary hypertension by at least three of the following metrics:

• - Elevated MPA pressure (early diastolic PR peak gradient >20 mmHg) - Right ventricular hypertrophy (qualitative as mild to severe) - Right atrial enlargement (scales for age will be provided) - Elevated right ventricular systolic pressure (>35mmHg) on at least two at least two reliable spectral Doppler envelopes during the echocardiogram and in the setting of normal for age documented systolic blood pressure at least two reliable spectral Doppler envelopes during the echocardiogram.

• - Flattening or (R to L) bowing of the interventricular septum (qualitative or by elevated eccentricity index) - Diminished RV function (RV fractional area change <35%) and/or TAPSE below published normal range for age and weight.

ii. There is no clinical or imaging evidence of left heart dysfunction; iii. Pulmonary venous stenosis and atresia are ruled out by CT angiography or MRI unless all four pulmonary veins are unequivocally normal on the two separate echocardiograms; iv. There is no evidence of hemodynamically significant left-to-right shunting across an unrestricted systemic to pulmonary shunt (this is unlikely to be a concern for PFO, small ASD, or restrictive PDA or VSD).

• - Age ≥3 months to < 18 years (until just before the 18th birthday); - WSPH groups 1 or 3 NOT due to unrepaired congenital heart disease (other than a patent foramen ovale), OR single ventricle, OR Eisenmenger's syndrome (PLEASE NOTE that only patients with Group 1.1, 1.2, 1.3, and 1.4.

4 or Group 3 PAH will be included and this does not include those with much rarer presentations with connective tissue disease, HIV infection, portal hypertension, schistosomiasis, or persistent PAH of the newborn);

• - Current WHO FC II or III.

Exclusion Criteria.

• - Inability or failure to provide informed consent; - The presence of syncope, overt RV failure, cyanotic "spells" or systemic hypotension within 4 weeks of enrollment; - Evidence of diffuse or focal pulmonary venous disease, left-sided heart functional disease; - Known hypersensitivity to metabolites, or formulation components such as vehicle, preservatives or fillers that are contained in the investigational drugs; - Pregnancy or breastfeeding; - Documented history in the medical record of noncompliance with other medical regimens within one year of screening; - Recent (within 1 year) history of alcohol or illicit drug abuse; - Participation in any clinical study involving another investigational drug or device within 4 weeks; - Comorbidities.

a. Disorders treated with cyclosporine A or glyburide. b. Disorders treated with CYP3A Inhibitors and Beta Blockers. c. Congenital heart disease that was repaired within 6 months of enrollment; i. A repaired patent ductus arteriosus within two months prior to enrollment does not constitute an exclusion. ii. Anatomic issues with a measured Qp:Qs on cardiac catheterization of 1.3 or less are not considered hemodynamically significant and will therefore not be exclusions (i.e. patent foramen ovale, atrial septal defect, small muscular ventricular septal defect, and patent ductus arteriosus)

• - Laboratory values of exclusion at the screening visit.

1. serum ALT or AST lab value that is > 2xULN. 2. serum bilirubin lab value that is > 1.5xULN. 3. creatinine clearance < 30 mL/min;

• - Inability to comply with all study procedures and availability for duration of study; - Inability to take oral medications as prescribed; - Inability to agree to lifestyle considerations throughout the study (please see section 5.3) and for four weeks thereafter.

• - Children over 1 year of age with WSPH group 1 PAH attributed to IPAH or HPAH who are robustly responsive to acute vasodilator testing and who might benefit from a first line trial of oral CCB therapy as assessed by the treating physician and as described in PAH guidelines.

A Phase III, randomized, open label, pragmatic trial to compare the safety and efficacy of first-line combination therapy (sildenafil and bosentan) to first-line monotherapy (sildenafil alone) in pediatric subjects with WHO Functional Classes II or III and precapillary pulmonary hypertension of Group 1 (PAH caused by idiopathic, heritable, drugs or toxins, congenital heart disease, or connective tissue disease) or Group 3 (PAH caused by lung disease or hypoxemia) according to the WHO (Nice) classification system. Precapillary pulmonary hypertension will be defined by standard criteria as mean pulmonary artery pressure over 25 mmHg and/or pulmonary vascular resistance index (PVRI) > 3, as well as pulmonary capillary wedge pressure (or left ventricular end diastolic pressure) ≤ 15 mmHg as determined by cardiac catheterization. For infants less than one year of age for whom cardiac catheterization is not considered as part of the clinical team's recommended approach, enrollment will be possible without catheterization if the following four criteria (i-iv) are met: i. Two separate echocardiograms clearly demonstrate pulmonary hypertension by at least three of the following metrics. 1. Elevated MPA pressure (early diastolic PR peak gradient >20 mmHg) 2. Right ventricular hypertrophy (qualitative as mild to severe) 3. Right atrial enlargement (scales for age will be provided) 4. Elevated right ventricular systolic pressure (>35mmHg) on at least two at least two reliable spectral Doppler envelopes during the echocardiogram and in the setting of normal for age documented systolic blood pressure at least two reliable spectral Doppler envelopes during the echocardiogram. 5. Flattening or (R to L) bowing of the interventricular septum (qualitative or by elevated eccentricity index) 6. Diminished RV function (RV fractional area change <35%) and/or TAPSE below published normal range for age and weight; ii. There is no clinical or imaging evidence of left heart dysfunction; iii. Pulmonary venous stenosis and atresia are ruled out by CT angiography or MRI unless all four pulmonary veins are unequivocally normal on the two separate echocardiograms; iv. There is no evidence of hemodynamically significant left-to-right shunting across an unrestricted systemic to pulmonary shunt. Study subjects will be followed with current standard of care assessments and diagnostics, including longitudinal clinical evaluations, determinations of functional class (FC), serial NT-pro-Brain Natriuretic Peptide (NT-proBNP) levels, and echocardiography. Data from these studies will be analyzed in central core facilities that will be used by all participating study sites. Clinical endpoints are the focus of this study. However, additional data collection is planned for exploratory aims to examine the potential role for future application of novel metrics of outcomes in children with PAH (e.g., pediatric QOL and actigraphy), as described below. The investigators also plan to collect blood, swab and urine samples to determine whether inherent genomic variations or novel proteomic biomarkers will associate with clinical responsiveness to interventions within the cohort. Bio-specimens will be obtained to further test the hypothesis that therapeutic responders will have a different genomic or proteomic profile as compared to subjects who do not respond well to therapy. Bio-specimens will include the following: 1. Blood for DNA, peripheral blood mononuclear cells, plasma, and serum; and. 2. Paired Box Gene (PAXgene) tubes for RNA and miRNA studies; and. 3. Urine for biomarker analysis. Because sildenafil and bosentan have different mechanisms of action targeting different intracellular pathways, combination therapy is a rational treatment strategy for pediatric patients with PAH. Past work in adult PAH suggests that combination therapy with longer duration agents with the same mechanisms of action may cause greater and more sustained improvement in clinical course in comparison with monotherapy. Whether children with PAH respond and tolerate combination therapy better than monotherapy has not been studied. In addition, despite a growing experience with sequential therapy, additional medications are added only after clinical deterioration or failure to sustain responsiveness. Pharmacokinetics will be assessed during this study in order to determine whether drug levels or compliance with therapy affect outcomes in this cohort. In addition, pharmacokinetics data and related clinical responses from mono- and dual therapy participants will be compared. Interactions between these agents are well known, whereby bosentan decreases sildenafil levels. As a result, sildenafil levels during mono- and combination therapy will be further defined by the planned pharmacokinetics in the current protocol. In addition to strengthening this current study design, such data will form a basis for optimizing the use of these agents and potential strategies for dose adjustments in the broader scope of clinical care in the future.

Arms

Active Comparator: Monotherapy with Sildenafil Group

mono-therapy: first-line monotherapy (sildenafil alone) - in pediatric subjects with PAH.

Active Comparator: Duo Therapy with Sildenafil + Bosentan Group

duo-therapy: compare two treatment strategies - first-line combination therapy (sildenafil and bosentan)

Interventions

Drug: - Mono-Therapy with Sildenafil

The subjects will be randomized to receive sildenafil alone and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.

Drug: - Duo-Therapy with Sildenafil + Bosentan

The subjects will be randomized to receive combination up-front therapy sildenafil and bosentan and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.